In the field of cancer treatment, chimeric antigen receptor T-cell (CAR-T) therapy stands out as a unique novel management approach for patients with certain types of blood cancers. Providing access to this groundbreaking therapy can create cancer survivors.

CAR-T cell therapy is a revolutionary form of immunotherapy that harnesses the power of a patient's own immune system to fight cancer

What is CAR-T cell therapy?

CAR-T cell therapy is a revolutionary form of immunotherapy that harnesses the power of a patient's own immune system to fight cancer. This personalised treatment involves collecting a patient's immune T-cells which may not be effective by themselves, genetically modifying them to produce chimeric antigen receptors (CARs) that can better recognise and attack cancer cells, multiplying the retrained T-cells, and then infusing the enhanced cells back into the patient's body. This process has shown success in treating certain blood cancers, including B-cell acute lymphoblastic leukemia, various types of non-Hodgkin's lymphoma, and multiple myeloma. Large international clinical trials as well as available realworld data have shown unprecedented benefits for patients with CAR-T cell therapy when no other standard treatment options may be available.

Benefits for insurers and brokers

By offering access to CAR-T cell therapy, insurers and brokers can provide their members with a cutting edge treatment option that has shown significant improvement in outcomes for cancer patients including, in some cases, those with end-stage disease. This not only enhances the value of your insurance plans but also demonstrates a commitment to providing the best possible care for your members.

By offering access to CAR-T cell therapy, insurers and brokers can provide their members with a cuttingedge treatment option that has shown significant improvement in outcomes

Why choose Mayo Clinic for CAR-T cell therapy?

Mayo Clinic's CAR-T Cell Therapy Program is certified to prescribe all available CAR-T cell products and offers a comprehensive, patientcentered approach to care. Patients at Mayo Clinic benefit from the expertise of a multidisciplinary team of specialists who collaborate with an integrated approach to provide the best possible outcomes. Mayo Clinic's commitment to offering all available cutting-edge treatment approaches, medical discovery, and clinical trials, ensures that patients have access to the latest and most effective treatments.

Mayo Clinic's CAR-T Cell Therapy Program includes a thorough evaluation process, personalised treatment plans, and ongoing support for patients and their families

Sikander Ailawadhi, M.D., Haematologist-Oncologist at Mayo Clinic, and the Lead for Cancer International, emphasised the transformative potential of CAR-T cell therapy: “CAR-T cell therapy offers hope to patients whose cancers have not responded to conventional treatments and even in such situations where no other conventional treatments exist.”

Comprehensive care and support

Mayo Clinic's CAR-T Cell Therapy Program includes a thorough evaluation process, personalised treatment plans, and ongoing support for patients and their families. The programme also offers financial coverage options and assistance with insurance approvals, ensuring a seamless experience for international patients.

Conclusion

As the field of cancer treatment continues to advance, CAR-T cell therapy represents a significant breakthrough in the fight against blood cancers with potential future offerings for certain solid organ cancers as well. By collaborating with Mayo Clinic, private medical insurers and insurance brokers can offer their members access to this life-changing therapy, providing hope and improved outcomes for patients worldwide.